teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 14 Projects Releases Packages Wiki Activity Actions 59

auto-fix: strip 3 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-16 15:54:37 +00:00
parent 92272eca05
commit f920e3d5eb
3 changed files with 3 additions and 3 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -50,7 +50,7 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
### Additional Evidence (extend)
*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -55,7 +55,7 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2
### Additional Evidence (extend)
*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16*
The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.

2
domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
View file

@ -39,7 +39,7 @@ The source does not provide granular income-stratified discontinuation rates, so
### Additional Evidence (confirm)
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16*
The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.